Food and Drug Administration staffers didn’t take a firm stance on Moderna Inc.’s application for a booster dose, indicating there may not be sufficient data to support the extra dose.

from MarketWatch.com - Top Stories https://ift.tt/3v6DsSh
via IFTTT
from MarketWatch.com - Top Stories https://ift.tt/3v6DsSh
via IFTTT
Kommentare
Kommentar veröffentlichen